These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 11873737)

  • 1. [Cracovian Program for Secondary Prevention of Ischaemic Heart Disease. The quality of care in the field of secondary prevention of ischaemic heart disease depends on where patients are treated in the postdischarge period].
    Jankowski P; Kawecka-Jaszcz K; Pajak A
    Przegl Lek; 2001; 58 Suppl 6():21-5. PubMed ID: 11873737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Krakow Program for Secondary Prevention of Ischaemic Heart Disease. Part III. Secondary prevention of ischaemic heart disease after discharge].
    Kawecka-Jaszcz K; Jankowski P; Pajak A; Dubiel J; Maciejewicz J; Piotrowski W; Smielak-Korombel W; Tracz W
    Przegl Lek; 2001; 58(11):964-8. PubMed ID: 11987836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Krakow Program for Secondary Prevention of Ischaemic Heart Disease. Part II. Secondary prevention of ischaemic heart disease during hospitalization].
    Kawecka-Jaszcz K; Jankowski P; Pajak A; Dubiel J; Maciejewicz J; Piotrowski W; Smielak-Korombel W; Tracz W
    Przegl Lek; 2001; 58(11):956-63. PubMed ID: 11987835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease during hospitalization in 1996-97 and 1998-99].
    Pajak A; Kawecka-Jaszcz K; Jankowski P; Bilo G; Dubiel JS; Maciejewicz J; Piotrowski W; Smielak-Korombel W; Tracz W
    Przegl Lek; 2003; 60(3):136-41. PubMed ID: 14575013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cracovian program for secondary prevention of ischemic heart disease. Secondary prevention of ischemic heart disease after discharge in 1997-98 and 1999-2000].
    Jankowski P; Kawecka-Jaszcz K; Pajak A; Bilo G; Dubiel JS; Maciejewicz J; Piotrowski W; Smielak-Korombel W; Tracz W
    Przegl Lek; 2003; 60(3):142-6. PubMed ID: 14575014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Krakow Program for Secondary Prevention of Ischaemic Heart Disease. Part I. Genesis and objectives].
    Kawecka-Jaszcz K; Pajak A; Jankowski P
    Przegl Lek; 2001; 58(11):953-5. PubMed ID: 11987834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of coronary artery disease in hospital practice over the decade 1996-2006. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and EUROASPIRE III surveys.
    Jankowski P; Kawecka-Jaszcz K; Pajak A; Surowiec S; Wolfshaut R; Loster M; Badacz L; Dubiel JS; Grodecki J; Grodzicki T; Maciejewicz J; Mirek-Bryniarska E; Piotrowski W; Smielak-Korombel W; Tracz W
    Kardiol Pol; 2009 Aug; 67(8A):970-7. PubMed ID: 19784901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys.
    Pajak A; Jankowski P; Kawecka-Jaszcz K; Surowiec S; Wolfshaut R; Loster M; Batko K; Badacz L; Dubiel JS; Grodecki J; Grodzicki T; Maciejewicz J; Mirek-Bryniarska E; Piotrowski W; Smielak-Korombel W; Tracz W
    Kardiol Pol; 2009 Dec; 67(12):1353-9. PubMed ID: 20054766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.
    EUROASPIRE II Study Group
    Eur Heart J; 2001 Apr; 22(7):554-72. PubMed ID: 11259143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current standard of care in patients affected by coronary heart disease in Italy: the MC'95 study.
    Magnani B; Dal Palù C; Zanchetti A;
    Ital Heart J; 2002 Feb; 3(2):86-95. PubMed ID: 11926017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [EUROASPIRE: survey conducted by the European Society of Cardiology on secondary prevention of coronary disease. Hungarian results].
    Ostör E; Jánosi A; Belatiny KA; Borbás S; Bradak A; Podmaniczky M
    Orv Hetil; 1999 Jan; 140(5):243-8. PubMed ID: 10064978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of secondary preventive medications after the first attack of acute coronary syndrome.
    Salomaa V; Pääkkönen R; Hämäläinen H; Niemi M; Klaukka T
    Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):386-91. PubMed ID: 17568237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary prevention in chronic coronary heart disease].
    Hunziker P; Bertel O
    Schweiz Med Wochenschr; 1997 Feb; 127(7):254-60. PubMed ID: 9157530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive vs non-invasive treatment in acute coronary syndromes and prior bypass surgery.
    Gurfinkel EP; Perez de la Hoz R; Brito VM; Duronto E; Dabbous OH; Gore JM; Anderson FA;
    Int J Cardiol; 2007 Jun; 119(1):65-72. PubMed ID: 17045681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional variation in medication following coronary events in Germany.
    Müller-Nordhorn J; Kulig M; Binting S; Völler H; Krobot KJ; Willich SN
    Int J Cardiol; 2005 Jun; 102(1):47-53. PubMed ID: 15939098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.